Kent Payne, PhD

Bio:

Dr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, operational excellence and product R&D. His leadership philosophy blends scientific rigor with strategic decision-making, enabling Wilmington PharmaTech to scale its capabilities while maintaining agility and quality. In support of Dr. Li, Kent oversees company-wide operational performance, ensuring the alignment of people, processes, and facilities as Wilmington PharmaTech continues its expansion in API, HPAPI, and integrated development services. He is a three time CEO with extensive executive experience in M&A and successfully leading offerings from target identification through commercialization for both small and large molecules including complex sterile, inhalation, oral, topical and oral solution formulations. Kent also serves as an Operating Partner for Curewell Capital and Board Director for GBI (a Signet Healthcare Partners company).   Dr. Payne previously was CEO of Aliri Bioanalytical (an Archimed Co.); Bioduro (an Advent International Co.), and Socorro Pharmaceuticals (a specialty generic Rx company).  He also led the initial angel investment and was Board Chairman for  PDS Biotechnology (NASDAQ: PDSB).